Jetra Therapeutics

About

Jetra Therapeutics develops an engineered IL-22 cell-signalling peptide biologic to reduce hepatocellular stress and fat accumulation, advancing optimisation, safety assessment, and clinical development for NAFLD/NASH.

Mission

Jetra Therapeutics is commercialising a targeted biologic—an engineered IL-22 cell-signalling peptide—developed by UQ researchers to reduce stress in liver cells and decrease fat accumulation in pre-clinical tests. The company is founded on intellectual property developed at Mater Research Institute (MRI-UQ) and licensed via UniQuest. Breakthrough discoveries were led by Professor Mike McGuckin, Professor John Prins and Dr Sumaira Hasnain. The programme targets obesity-related liver disorders including NAFLD and NASH, conditions with high unmet clinical need and growing clinical impact. Jetra plans to further optimise the IL-22 therapy, assess safety, and subsequently undertake clinical trials. An initial investment from IP Group will support these translational activities.

Quick Facts